Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
Go back to Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors| (NASDAQ: AKTS) | Delayed: 27.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.01 | 52 Week High | $5.77 | |||
| Open | $27.01 | 52 Week Low | $1.51 | |||
| Day High | $27.01 | P/E | N/A | |||
| Day Low | $27.01 | EPS | $0.00 | |||
| Volume | 1,087 | |||||
